Price
No data yet.
Social Signal Score
Revenue
$2.60M+3617.14%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Eran Ophir
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 75
- Beta
- 2.78
- Country
- IL
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 0.54
Financials
Revenue
$2.60M+3617.1%Net Income
$-7.01MEBITDA
$-7.00MFree Cash Flow
$0.00-100.0%EPS (diluted)
$-0.07Shares Outstanding (diluted)
94.64M+85.8%Operating Expenses
$8.74MCash & Debt
$125.30MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $72.76M | $35.34M | $0.38 |
| 2024 | $27.86M | $-14.23M | $-0.16 |
| 2023 | $33.46M | $-18.75M | $-0.21 |
| 2022 | $7.50M | $-33.69M | $-0.39 |
| 2021 | $6.00M | $-34.20M | $-0.41 |
| 2020 | $2.00M | $-29.70M | $-0.37 |
| 2019 | $0.00 | $-27.34M | $-0.43 |
| 2018 | $17.80M | $-22.60M | $-0.41 |
| 2017 | $0.00 | $-37.07M | $-0.72 |
| 2016 | $712.0K | $-31.51M | $-0.62 |
| 2015 | $9.28M | $-20.16M | $-0.40 |
| 2014 | $12.37M | $-11.09M | $-0.23 |
| 2013 | $3.55M | $-14.08M | $-0.36 |
| 2012 | $242.0K | $-13.63M | $-0.38 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.56
- Implied price
- $2.22
- Return from $2.56
- -2.8% a year
To earn 15.0% a year on these assumptions you'd need to buy at $1.11 — -56.8% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 0 | 2 | 4 | 6 | 8 |
|---|---|---|---|---|---|
| -2.0% | — | -23.2% | -11.8% | -4.3% | 1.3% |
| 3.0% | — | -19.3% | -7.3% | 0.6% | 6.5% |
| 8.0% | — | -15.4% | -2.8% | 5.4% | 11.7% |
| 13.0% | — | -11.4% | 1.7% | 10.3% | 16.8% |
| 18.0% | — | -7.5% | 6.2% | 15.2% | 22.0% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
125Social Signal Score
Mentions (1)
- Newszacks.com·7h ago·Positive
All You Need to Know About Compugen (CGEN) Rating Upgrade to Buy Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
View source ↗
Earnings
Mon, Nov 9(in 2 months)
Consensus estimate $-0.07 per share
Typical surprise -14.3% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 3$-0.07 vs $-0.08beat
- Mon, May 18$-0.08 vs $-0.07miss
- Mon, Mar 2$0.60 vs $-0.07beat
- Mon, Nov 10$-0.07 vs $-0.09beat
- Wed, Aug 6$-0.08 vs $-0.07miss
- Mon, May 19$-0.08 vs $-0.06miss
Estimates and results for CGEN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CGEN officers and directors.
- Bought
- —
- Sold
- $118k
0 trades
11 trades
- Levine Zuritsold
- Levine Zuritsold
- Ophir Eransold
- Ophir Eransold
- Levine Zuritsold
- Levine Zuritsold
- Levine Zuritsold
- Levine Zuritsold
89 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.